Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The decision balances your weight loss goals against your feeding preferences and your infant's health needs, requiring personalized medical judgment rather than a universal timeline
approved alternatives include semaglutide (Wegovy) and tirzepatide (Mounjaro)
(2021) trial tested cagrilintide at 0.3-4.5 mg weekly for 26 weeks in 706 adults: (Lau et al., 2021) Semaglutide Monotherapy (Phase 3) The STEP 1 trial tested semaglutide 2.4 mg weekly for 68 weeks in 1,961 adults: Mean weight loss: -14.9% =10% threshold: ~70% =15% threshold: ~54% =20% threshold: ~32% Important caveat: The semaglutide trial was 68 weeks versus only 26 weeks for cagrilintide
Chronic TE lasts longer than six months and may require specialist investigation to identify underlying causes or coexisting conditions
US$ 20.31
US$ 20.56
US$ 20.96
US$ 28.52
